PMID- 32405660
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20220531
IS  - 1433-3023 (Electronic)
IS  - 0937-3462 (Linking)
VI  - 32
IP  - 5
DP  - 2021 May
TI  - Is imidafenacin an alternative to current antimuscarinic drugs for patients with 
      overactive bladder syndrome?
PG  - 1117-1127
LID - 10.1007/s00192-020-04329-x [doi]
AB  - PURPOSE: Previous studies have included a limited number of randomized controlled 
      trials (RCTs) and compared limited parameters after treatment with imidafenacin 
      and other anticholinergic drugs (ADs) for overactive bladder syndrome (OAB), and 
      controversy about the superiority of these ADs still remains. We aim to update 
      the evidence and provide better clinical guidance. METHODS: A systematic search 
      of PubMed, Embase, ClinicalTrial.gov and Cochrane Library Central Register of 
      Controlled Trials was conducted from January 2007 to April 2019. Meta-analysis of 
      all published RCTs comparing imidafenacin with other ADs in patients with OAB was 
      performed. The primary outcomes were the changes in OAB symptoms and OAB symptom 
      score (OABSS). Secondary outcomes included adverse events (AEs) and the dropout 
      rate related to AEs. RESULTS: A total of 6 studies including 7 RCTs involving 
      1430 patients with mean follow-up of 23.43 weeks were included. All ADs improved 
      OAB symptoms. Regarding efficacy, these drugs had similar efficacy in voids, 
      urgency episodes, urgency incontinence episodes, incontinence episodes and OABSS. 
      However, imidafenacin performed better in the reduction of nocturia episodes 
      (MD = -0.24, 95% CI -0.44 to -0.04, P = 0.02). Moreover, imidafenacin was 
      associated with a statistically lower dry mouth rate (RR = 0.87, 95% CI 
      0.75-1.00, P = 0.04), lower constipation rate (RR = 0.68, 95% CI 0.50-0.93, 
      P = 0.01) and lower AE-related withdrawal rate (RR = 0.51, 95% CI 0.29-0.89, 
      P = 0.02). There was no significant difference in terms of other complications. 
      CONCLUSIONS: In conclusion, imidafenacin was comparable to other ADs in the 
      treatment of OAB. Moreover, imidafenacin presented a lower dry mouth rate, lower 
      constipation rate and higher adherence and persistence.
FAU - Wu, Jia-Pei
AU  - Wu JP
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, 610041, People's Republic of China.
FAU - Peng, Liao
AU  - Peng L
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, 610041, People's Republic of China.
FAU - Zeng, Xiao
AU  - Zeng X
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, 610041, People's Republic of China.
FAU - Li, Hao
AU  - Li H
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, 610041, People's Republic of China.
FAU - Shen, Hong
AU  - Shen H
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, 610041, People's Republic of China.
FAU - Luo, De-Yi
AU  - Luo DY
AUID- ORCID: 0000-0002-9436-036X
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu, Sichuan, 610041, People's Republic of China. 
      luodeyi1985@163.com.
LA  - eng
GR  - 81770673/the National Natural Science Fund of China/
GR  - ZY2017310/1.3.5 project for disciplines of excellence, West China Hospital, 
      Sichuan University/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200514
PL  - England
TA  - Int Urogynecol J
JT  - International urogynecology journal
JID - 101567041
RN  - 0 (Imidazoles)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Pharmaceutical Preparations)
RN  - XJR8Y07LJO (imidafenacin)
SB  - IM
MH  - Humans
MH  - Imidazoles
MH  - Muscarinic Antagonists
MH  - *Pharmaceutical Preparations
MH  - Treatment Outcome
MH  - *Urinary Bladder, Overactive
OTO - NOTNLM
OT  - Anticholinergic drug
OT  - Antimuscarinics
OT  - Imidafenacin
OT  - Novel antimuscarinic agent
OT  - Overactive bladder syndrome
OT  - Quality of life
EDAT- 2020/05/15 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/05/15 06:00
PHST- 2020/02/08 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/05/15 06:00 [entrez]
AID - 10.1007/s00192-020-04329-x [pii]
AID - 10.1007/s00192-020-04329-x [doi]
PST - ppublish
SO  - Int Urogynecol J. 2021 May;32(5):1117-1127. doi: 10.1007/s00192-020-04329-x. Epub 
      2020 May 14.